Changeflow GovPing Pharma & Drug Safety Pharmaceutical Composition Comprising Lipoic Ac...
Routine Rule Added Final

Pharmaceutical Composition Comprising Lipoic Acid and Taurine as Osmoprotective Agent

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO granted Patent EP3297733A1 to Dulcis Health Science for a pharmaceutical composition combining lipoic acid and taurine as an osmoprotective agent. The patent, published April 8, 2026, lists inventors Claret, Martine, Claret, Claude, and Chatard-Baptist, Caroline, with designations covering all 31 European Patent Convention member states.

Published by Dulcis Health on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO granted EP3297733A1, a patent for pharmaceutical compositions comprising lipoic acid and taurine as osmoprotective agents. The patent covers various formulations including topical, oral, and injectable preparations, classified under A61K and A23L categories.

For pharmaceutical companies and researchers developing osmoprotective formulations, this patent establishes proprietary rights in the European market. Competitors may need to pursue licensing negotiations or develop non-infringing alternatives to commercialize similar products in EPC-designated states.

What to do next

  1. Monitor for potential infringement if developing competing osmoprotective formulations
  2. Review patent claims to assess freedom to operate

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF LIPOIC ACID AND TAURINE AS OSMOPROTECTIVE AGENT

Publication EP3297733A1 Kind: A1 Apr 08, 2026

Applicants

DULCIS HEALTH SCIENCE

Inventors

CLARET, Martine, CLARET, Claude, CHATARD-BAPTISTE, Caroline

IPC Classifications

A61K 31/185 20060101AFI20260127BHEP A61K 31/385 20060101ALI20260127BHEP A61K 8/46 20060101ALI20260127BHEP A23L 33/10 20160101ALI20260127BHEP A23L 33/12 20160101ALI20260127BHEP A23L 33/175 20160101ALI20260127BHEP A61K 8/49 20060101ALI20260127BHEP A61K 9/00 20060101ALI20260127BHEP A61K 9/06 20060101ALI20260127BHEP A61K 9/14 20060101ALI20260127BHEP A61P 17/00 20060101ALI20260127BHEP A61P 27/00 20060101ALI20260127BHEP A61Q 19/00 20060101ALI20260127BHEP A61P 27/02 20060101ALI20260127BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from Dulcis Health.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
Dulcis Health
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3297733A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent licensing Drug formulation IP protection
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!